Liraglutide significantly reduces lipid droplet formation and myocardial fibrosis in models.
Liraglutide decreases expression of fibrosis markers, such as TGF-β1 and collagen types I and III.
Increased activation of AMP-activated protein kinase (AMPK) is observed with liraglutide treatment.
Enhanced mitochondrial function and antioxidant gene expression are associated with liraglutide use.
Liraglutide may improve insulin signaling and reduce oxidative stress in cardiomyocytes.
Simplified
BACKGROUND: Diabetes is a primary contributor to (DbCM), which is marked by metabolic imbalances such as elevated blood glucose and lipid levels, leading to significant structural and functional alterations in the myocardium. Elevated free fatty acids (FFAs) and hyperglycemia play critical roles in DbCM development, with FFAs inducing insulin resistance in cardiomyocytes and promoting lipid accumulation, resulting in oxidative stress and fibrosis. Current research suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may effectively mitigate DbCM, although an effective treatment for this condition remains elusive, and the precise mechanisms of this protective effect are not fully understood.
METHODS: In this study, we aimed to replicate diabetic glucolipotoxic conditions by treating differentiated H9c2 cells with high glucose and free fatty acids. Additionally, a diabetic cardiomyopathy model was induced in mice through high-fat diets. Both in vitro and in vivo models were used to investigate the protective effects of liraglutide on cardiomyocytes and elucidate its underlying molecular mechanisms.
RESULTS: Our findings indicate that liraglutide significantly reduces lipid droplet (LD) formation and myocardial fibrosis, as evidenced by decreased expression of fibrosis markers, including TGF-β1 and collagen types I and III. Liraglutide also enhanced AMP-activated protein kinase (AMPK) activation, which improved mitochondrial function, increased antioxidant gene expression, enhanced insulin signaling, and reduced oxidative stress.
CONCLUSIONS: These results demonstrate the potential therapeutic role of liraglutide in managing diabetes-related cardiac complications, offering a comprehensive approach to improving cardiac outcomes in patients with diabetes.
Key numbers
100%
Increase in MDA Levels
MDA content measurement shows a significant increase with + treatment.
0.4 mg/kg
Dose
was given subcutaneously twice weekly for 24 weeks.
Full Text
We can’t show the full text here under this license.
Declarations. Conflict of interest: The authors declare that they have no competing interests. Ethical approval and consent to participate: This research was established following the guidelines of the Institutional Animal Care and Use Committee (IACUC) of Chung Shan Medical University granted approval for this study with approval No. 2673. Consent for publication: All authors reviewed the results and approved this manuscript for publication.
PubMed
Weekly GLP-1 Therapies Brief
You found one interesting study. We’ll send the next 7.
Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.
